文献速递关节外科

AAHKS临床研究奖:预防性坦索罗辛不能降低下肢关节置换术后尿潴留风险:一项双盲随机对照试验

The AAHKS Clinical Research Award: Prophylactic Tamsulosin Does Not Reduce the Risk of Urinary Retention Following Lower Extremity Arthroplasty: A Double-Blinded Randomized Controlled Trial.
PubMed 文献 · J Arthroplasty · 2019-03-20

这项双盲随机对照试验纳入176例35岁及以上行初次全髋或全膝关节置换术的男性患者,随机接受坦索罗辛0.4 mg或安慰剂每日一次,术前5天、手术当日晨及术后第1天给药。最终131例完成研究,坦索罗辛组尿潴留发生18例(28.1%),安慰剂组24例(35.8%),差异无统计学意义(P=0.345)。结论:预防性坦索罗辛未降低髋膝关节置换术后尿潴留发生率。

要点

  • 预防性坦索罗辛未降低髋膝关节置换术后尿潴留发生率。
  • 坦索罗辛组尿潴留18例(28.1%),安慰剂组24例(35.8%),P=0.345。
  • 坦索罗辛组发生尿潴留的比值比为0.701,风险差为7.69%。

核心结论

  • 与安慰剂相比,预防性坦索罗辛未降低髋膝关节置换术后尿潴留的发生率。
  • 比值比提示坦索罗辛组发生尿潴留的比值约降低30%,但未达统计学显著。
  • 坦索罗辛似乎不能有效作为减少男性髋膝关节置换患者术后尿潴留的预防措施。

研究设计与样本

  • 双盲随机对照试验,2015年至2018年单中心纳入35岁及以上行初次全髋或全膝关节置换术的男性患者。
  • 患者随机接受坦索罗辛0.4 mg或安慰剂每日一次,术前5天、手术当日晨及术后第1天给药。
  • 共176例入组,随机化前退出2例,174例随机分为坦索罗辛组(n=87)和安慰剂组(n=87)。
  • 手术前额外退出43例,最终131例完成研究(坦索罗辛组n=64,安慰剂组n=67)。

主要发现

  • 42例(32.1%)发生术后尿潴留,其中坦索罗辛组18例(28.1%),安慰剂组24例(35.8%)(P=0.345)。
  • 坦索罗辛组发生尿潴留的比值比为0.701,风险差为7.69%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative urinary retention (POUR) is common. Selective alpha-1 adrenergic antagonists, such as tamsulosin, are effective for treating urinary retention. The purpose of this study is to determine whether perioperative prophylactic tamsulosin reduces the incidence of POUR following total hip and knee arthroplasty. METHODS: Male patients 35 years of age and older undergoing primary total hip or knee arthroplasty at a single center from 2015 to 2018 were eligible for inclusion. Patients were randomized to receive tamsulosin 0.4 mg or placebo daily for 5 days preoperatively, the morning of surgery, and the first postoperative day. The incidence of POUR was determined during the postoperative hospitalization. RESULTS: A total of 176 patients were enrolled in the study. Two patients were withdrawn prior to randomization. The remaining 174 were randomized to tamsulosin (n = 87) or placebo (n = 87). After an additional 43 patients were withdrawn prior to surgery, 131 patients completed the study (tamsulosin, n = 64; placebo, n = 67). A total of 42 patients (32.1%) developed POUR, with 18 cases (28.1%) in the tamsulosin group and 24 cases (35.8%) in the placebo group (P = .345), resulting in an odds ratio of 0.701 and a risk difference of 7.69%. CONCLUSION: Prophylactic tamsulosin did not reduce the incidence of POUR after hip and knee arthroplasty compared to placebo. The odds ratio indicates an approximately 30% decreased odds of developing POUR in the tamsulosin group, albeit not statistically significant. Tamsulosin does not appear to be effective as a prophylactic measure for reducing POUR in male hip and knee arthroplasty patients.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Schubert MF, Thomas JR, Gagnier JJ, et al. The AAHKS Clinical Research Award: Prophylactic Tamsulosin Does Not Reduce the Risk of Urinary Retention Following Lower Extremity Arthroplasty: A Double-Blinded Randomized Controlled Trial. J Arthroplasty. 2019. PMID: 30982761. doi:10.1016/j.arth.2019.03.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。